<DOC>
	<DOCNO>NCT01154088</DOCNO>
	<brief_summary>The purpose observer-blinded study determine immunogenicity safety one dose GlaxoSmithKline ( GSK ) Biologicals ' meningococcal vaccine GSK 134612 compare one dose Mencevax™ ACWY healthy subject 18-25 year age . In addition , study compare immunogenicity two lot GSK 's 134612 vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY Healthy 18-25 Year Olds</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : Subjects investigator believe comply requirement protocol enrol study . A male female , include , 18 25 year age time vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month vaccination . The following criterion check time study entry . If exclusion criterion applies , subject must include study : Use investigational nonregistered product study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccination . ( For corticosteroid , mean prednisone &lt; 10 mg/day , equivalent , allow . Inhaled topical steroid allow ) . Planned administration/administration vaccine foreseen study protocol within one month dose vaccine , exception license inactivated influenza vaccine , include H1N1 vaccine . Previous vaccination meningococcal polysaccharide vaccine within last five year . Previous vaccination meningococcal conjugate vaccine . Previous vaccination tetanustoxoid tetanustoxoid contain vaccine within last month . History meningococcal disease . Seropositive HIV HBsAg ( subject Philippines ) . Any confirm suspect immunosuppressive immunodeficient condition , include human immunodeficiency virus infection , base medical history physical examination . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History reaction allergic disease likely exacerbate component either vaccine . History neurologic disorder , include GuillainBarré Syndrome . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede dose study vaccine plan administration study period . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution . Bleeding disorder , thrombocytopenia , subject anticoagulant therapy . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Adolescent</keyword>
	<keyword>Vaccine , conjugate</keyword>
	<keyword>Adult</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Safety</keyword>
</DOC>